+1-786-628-7980
Sign Up/Sign In 
The market size of the Global Acute Vulvovaginal Candidiasis Treatment Market in the year 2021 is valued at 320.77 million and is predicted to reach 485.54 million by the year 2030 at 4.8% CAGR during the forecast period.
The development of numerous treatments and drugs for the treatment of acute vulvovaginal candidiasis is part of the acute vulvovaginal candidiasis market. Acute vulvovaginal candidiasis (VVC), often known as vaginal thrush, is a yeast infection caused by the candida albicans fungus. An overgrowth of fungus causes the infection, which causes symptoms such as abnormal vaginal discharge, intense pain during intercourse, and vaginal itching. The VVC is expected to affect 75% of women at some point in their lives. The majority of VVC instances are minor, but in some women, the infection can become severe, resulting in swelling, cracks in the vaginal wall, and redness. Moreover, the demand for acute vulvovaginal candidiasis treatment is rising in tandem with the worldwide disease burden, expanding desire for better treatment choices, and an increase in the number of hospital-acquired infections. Furthermore, market players are in high competition to submit new drug applications (NDAs) to regulatory agencies to grant them approval to manufacture their products. The global acute vulvovaginal candidiasis market is predicted to increase as a result of this aspect.
Curious about this latest version of report? Obtain Report Details @ https://www.insightaceanalytic.com/report/-acute-vulvovaginal-candidiasis-market-/1232
List of Prominent Players in the Acute Vulvovaginal Candidiasis Treatment Market:
Mycovia Pharmaceuticals, Inc.
Scynexis, Inc.
Basilea Pharmaceutica Ltd.
Astellas Pharma Inc.
Grupo Ferrer Internacional, S.A.
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc.
Cidara Therapeutics, Inc.
Padagis LLC
ProFem GmbH
Amplyx Pharmaceuticals Inc.
MethylGene Inc.
Ferrer Internacional S.A.
Pfizer, Inc.
Other Prominent Players
For More Information @https://www.insightaceanalytic.com/report/-acute-vulvovaginal-candidiasis-market-/1232
Market Dynamics:
Drivers:
The global acute vulvovaginal candidiasis treatment market is expected to grow at a significant rate during the forecast period. The global demand for yeast infection treatment medications is predicted to rise due to the rapid expansion and unrestricted use of antibiotics, which has resulted in a high prevalence of yeast infection. Moreover, the demand for acute vulvovaginal candidiasis treatment is rising in tandem with the worldwide disease burden, expanding desire for better treatment choices, and an increase in the number of hospital-acquired infections. Numerous factors driving the global acute vulvovaginal candidiasis treatment market include the development of new antifungal medications, an increase in healthcare spending, and the expansion of healthcare infrastructure.
Challenges:
The global acute vulvovaginal candidiasis therapy market is expected to be hampered by the prevalence of the COVID-19 pandemic during the forecasted period. The COVID-19 pandemic has impeded the conduct of clinical trials, according to the Indian Journal of Medical Sciences on June 6, 2020, due to a lack of trial site staff, travel limitations, experimental product supply, and other factors. These obstacles obstruct the development of new treatments for acute vulvovaginal candidiasis. Candida infection is becoming more common among patients in intensive care units. Moreover, due to the lockdown and social distancing norms, significant corporations have halted operations in several areas. Following the pandemic, the industry forecasts a high level of demand and supply because of the expansion in urbanization and the rising desire to make optimal use of space.
Regional Trends:
The Asia Pacific acute vulvovaginal candidiasis market is expected to rise significantly during the projected period. Increasing awareness of this illness among rural women, as well as Indian government programmes such as ‘Swachhta, Swasthya, and Suvidha’ to improve the cleanliness of poor women, are boosting the global acute vulvovaginal candidiasis market in this area. Moreover, due to improved healthcare infrastructure, economic growth, an increase in the number of insurance payers, the rapid development of the private healthcare sector, and an increase in education and awareness, developing countries such as Japan and China are expected to contribute to the market expansion in the Asia Pacific. However, North America is predicted to grow rapidly in the global acute vulvovaginal candidiasis market over the forecast period.
Recent Developments:
In June 2021, Scynexis had reached an agreement with Amplity Health, a pharmaceutical company, to extend its support for the commercialization of BrexafemmeTM, a brand name of Ibrexafungerp for vaginal infections, in the United States.
Acute Vulvovaginal Candidiasis Treatment Market Segmentation:
Acute Vulvovaginal Candidiasis Treatment Market Segmentation: By Drug Type Estimates & Trend Analysis
Acute Vulvovaginal Candidiasis Treatment Market Segmentation: By Route of Administration Estimates & Trend Analysis
Acute Vulvovaginal Candidiasis Treatment Market Segmentation: By Distribution Channels Estimates & Trend Analysis
Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1232
